Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611001017910
Ethics application status
Approved
Date submitted
12/09/2011
Date registered
22/09/2011
Date last updated
22/09/2011
Type of registration
Retrospectively registered

Titles & IDs
Public title
MATADOR: Minimising Adaptive Thermogenesis And Deactivating Obesity Rebound
Scientific title
Effect of Intermittent Versus Continuous Energy Restriction on Body Weight, Resting Metabolic Rate and Neuroendocrine Function in Obese Men.
Secondary ID [1] 263026 0
Nil
Universal Trial Number (UTN)
U1111-1124-4910
Trial acronym
MATADOR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obesity 270752 0
Condition category
Condition code
Metabolic and Endocrine 270932 270932 0 0
Normal metabolism and endocrine development and function
Diet and Nutrition 270942 270942 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The study will comprise 3 phases: [1] Baseline energy balance, [2] Energy restriction intervention, and [3] Post-intervention energy balance. As we have previously shown that provision of food maximises dietary compliance in the free-living situation (1,2,4), food will be home-delivered weekly to participants in all phases of this study. The aim of PHASE 1 is to determine the baseline values of various parameters of the famine reaction before energy restriction and weight loss. During the 4 weeks of PHASE 1, weight stability will be achieved as we have previously published (1-4), by determining maintenance energy requirements from dietary history and resting metabolic rate (RMR), and then providing participants with a weight maintenance diet. In PHASE 2, participants will be randomised to continuous or intermittent energy restriction interventions. The continuous intervention consists of 16 weeks on a diet at 67% of maintenance energy requirements. The intermittent intervention consists of 16 weeks of total energy restriction administered as 2 weeks of energy restriction on a diet at 67% of maintenance energy requirements followed by 2 weeks of energy balance on a diet at 100% of maintenance energy requirements, for a total of 30 weeks. The interventions are designed to elicit a 10% body weight loss. To account for weight lost, the energy restriction will be indexed to body weight and RMR after every 4 weeks of energy restriction, thereby keeping theoretical relative energy deficit consistent across the 16-week period. In PHASE 3, participants will be placed on an energy balance diet referenced to their reduced-weight state for 4 weeks to examine the time course of recovery of metabolic and neuroendocrine markers. The macronutrient distribution in both energy restriction and energy balance diets will be maintained within the range of 25–30% of energy as fat, 15-20% as protein, and 50–60% as carbohydrate. As we have previously shown that provision of food maximises dietary compliance in the free-living situation (1,2,4), food will be home-delivered weekly to participants in this study.

1. Weinsier RL, Hunter GR, Desmond RA, Byrne NM, Zuckerman PA, Darnell BE. Free-living activity energy expenditure in women successful and unsuccessful at maintaining a normal body weight. Am J Clin Nutr. 2002; 75(3):499-504.
2. Byrne NM, Hills AP, Wood RE. Does body composition, relative energy deficit or adaptive thermogenesis explain differences between predicted and actual weight loss in obese adults? Obesity Reviews. 2010;11(Suppl.1):35-36.
3. Byrne NM, Weinsier RL, Hunter GR, et al. Influence of distribution of lean body mass on resting metabolic rate after weight loss and weight regain: comparison of responses in white and black women. Am J Clin Nutr. 2003;77(6):1368-73.
4. Wood RE, Byrne NM, Groves AM, Hills AP, King NK. Achieving energy balance in apparently sedentary obese males. Obesity Reviews. 2010;11(Suppl.1):219.
Intervention code [1] 269368 0
Treatment: Other
Intervention code [2] 269376 0
Lifestyle
Comparator / control treatment
Continuous Energy Restriction is the control treatment
Control group
Active

Outcomes
Primary outcome [1] 279596 0
Body weight will be measured using digital weighing scales. Digital weighing scales are to be used to monitor body weight of participants at home in times between laboratory visits. These scales will be calibrated regularly, and weight will also be measured at the standard laboratory sessions.
Timepoint [1] 279596 0
Daily - 4 weeks energy balance (pre-intervention)
Daily - 16 weeks (continuous) or 30 weeks (intermittent) energy restriction
Daily - 4 weeks energy balance (post-intervention)
Primary outcome [2] 279599 0
Resting metabolic rate via indirect calorimetry
Timepoint [2] 279599 0
Week 1 and 4 - energy balance (pre-intervention)
Week 4, 8, 12 and 16 - energy restriction
Week 2, 4 - energy balance (post-intervention)
Primary outcome [3] 279600 0
Neuroendocrine status: Overnight fasted blood samples will be collected and concentrations of the following analytes in serum or plasma will be determined: free T3, Free T4, reverse T3, TSH, ACTH, cortisol, testosterone, sex hormone binding globulin, IGF-1, and leptin.
Timepoint [3] 279600 0
Week 1 and 4 - energy balance (pre-intervention)
Week 4, 8, 12 and 16 - energy restriction
Week 1, 2, 4 - energy balance (post-intervention)
Secondary outcome [1] 294010 0
Body composition (Fat Mass and Fat-free Mass) will be assessed using the gold-standard 4-compartment model using air displacement plethysmography (via BodPod), deuterium dilution and Dual Energy X-ray Absorptiometry (DXA) at 4 time points: in energy balance immediately prior to (Phase 1), midway and immediately after the weight loss intervention (Phase 2) and after the 4-wk period of energy balance (Phase 3). In addition, BodPod measurements will be taken at week 1 energy balance (pre-intervention), weeks 4 and 12 of energy restriction, and weeks 1 and 2 of energy balance (post-intervention).
Timepoint [1] 294010 0
Week 1 and 4 - energy balance (pre-intervention)
Week 4, 8, 12 and 16 - energy restriction
Week 1, 2, 4 - energy balance (post-intervention)
Secondary outcome [2] 294011 0
Fasting substrate oxidation via indriect calorimetry
Timepoint [2] 294011 0
Week 1 and 4 - energy balance (pre-intervention)
Week 4, 8, 12 and 16 - energy restriction
Week 2, 4 - energy balance (post-intervention)
Secondary outcome [3] 294012 0
Markers of metabolic health (fasting serum glucose, insulin, triglycerides, cholesterol)
Timepoint [3] 294012 0
Week 1 and 4 - energy balance (pre-intervention)
Week 4, 8, 12 and 16 - energy restriction
Week 1, 2, 4 - energy balance (post-intervention)

Eligibility
Key inclusion criteria
Sedentary (< 60 mins physical activity per week)
Class I or II obese (30-40kg.m-2)
Waist circumference >102 cm
Euthyroid, non-diabetic, ambulatory, and weight stable for at least 6 months (+/-2kg)
Minimum age
25 Years
Maximum age
53 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
Diabetic or fasting blood glucose > 6.0 mmol/L (from medical screening)
Major surgery that will affect gut function/metabolic rate
Arthritis/musculoskeletal problems that would preclude full participation in all testing/affect activities of daily living
Heart condition
Sleep apnoea
Thyroid condition
Current smoker or gave up smoking within the last 6 months
Any medications known to affect metabolic rate or neuroendocrine function
Non-ambulatory
Currently on a “diet” or actively losing weight

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be stratified according to BMI (30-34.9, 35-40) and age (25-38.9, 39-53) and then randomly allocated into either the intermittent energy restriction or continuous energy restriction groups.
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Pemuted block randomisation. Where intermittent energy restriction = 1 and continuous energy restriction = 2.
Where BMI (30-34.9) = A, BMI (35-40) = B, Age (25-38.9) = C, Age (39-53) = D. Each participant will therefore fall into one of four cell options: AC, AD, BC or BD. Each cell will have pair allocations of random sequence 1 or 2.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
6/03/2009
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 269828 0
Government body
Name [1] 269828 0
National Health and Medical Research Council
Country [1] 269828 0
Australia
Primary sponsor type
Individual
Name
Professor Nuala Byrne
Address
Institute of Health and Biomedical Innovation
Queensland University of Technology
60 Musk Avenue
Kelvin Grove QLD 4059
Country
Australia
Secondary sponsor category [1] 268860 0
University
Name [1] 268860 0
Queensland University of Technology
Address [1] 268860 0
2 George Street
Brisbane, QLD 4000
Country [1] 268860 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 271796 0
University Human Research Ethics Committee (UHREC)
Ethics committee address [1] 271796 0
Ethics committee country [1] 271796 0
Australia
Date submitted for ethics approval [1] 271796 0
Approval date [1] 271796 0
08/04/2008
Ethics approval number [1] 271796 0
0800000081

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33143 0
Address 33143 0
Country 33143 0
Phone 33143 0
Fax 33143 0
Email 33143 0
Contact person for public queries
Name 16390 0
Professor Nuala Byrne
Address 16390 0
Institute of Health and Biomedical Innovation
Queensland University of Technology
60 Musk Avenue
Kelvin Grove, QLD4059
Country 16390 0
Australia
Phone 16390 0
61 7 3138 6088
Fax 16390 0
61 7 3138 3606
Email 16390 0
[email protected]
Contact person for scientific queries
Name 7318 0
Professor Nuala Byrne
Address 7318 0
Institute of Health and Biomedical Innovation
Queensland University of Technology
60 Musk Avenue
Kelvin Grove, QLD4059
Country 7318 0
Australia
Phone 7318 0
61 7 3138 6088
Fax 7318 0
61 7 3138 3606
Email 7318 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe neuropeptide Y-ergic system: Potential therapeutic target against bone loss with obesity treatments.2015https://dx.doi.org/10.1586/17446651.2015.1001741
N.B. These documents automatically identified may not have been verified by the study sponsor.